News Releases

Decreases workforce by approximately 50% and reduces commercial manufacturing expenses to prioritize spend towards topline clinical data readouts for CAN-2409 in non-small cell lung cancer, pancreatic cancer, and prostate cancer in 2024 Prioritizes development of CAN-3110 in recurrent high-grade

Initial survival data from phase 2 clinical trial of CAN-2409 in advanced non-small cell lung cancer (NSCLC) showed survival supportive of an increased tail on the maturing survival curve Initial data from phase 2 clinical trial of CAN-2409 in borderline resectable pancreatic cancer demonstrated an

The first experimental agent from the enLIGHTEN™ Discovery Platform is Alpha-201-macro1, an investigational viral immunotherapy designed to activate innate immune surveillance Application of the enLIGHTEN™ Advanced Analytics suite to datasets from immune checkpoint inhibitor (ICI)-treated patients

Initial positive interim data revealed notable improvements in patients with borderline resectable pancreatic ductal adenorcarcinoma (PDAC) after experimental treatment with CAN-2409 Estimated overall survival rate was 71.4% at 36 months in CAN-2409 treated patients versus 16.7% in the control arm

CAN-3110 is a first-in-class herpes simplex virus-1 oncolytic immunotherapy candidate with dual activity for oncolysis and immune activation in a single therapeutic In a first-in-human clinical trial of CAN-3110 in recurrent high-grade glioma, CAN-3110 was well tolerated and treatment was associate

One clinical poster detailing initial overall survival and immunological biomarker data from the ongoing, randomized, open-label phase 2 clinical trial of CAN-2409 plus standard of care chemoradiation in pancreatic cancer Two preclinical posters characterizing new developments from the enLIGHTEN ™

Initial data suggests 12-month survival is consistent with an increased tail on the maturing survival curve Negative or low PD-L1 status appears to be associated with long survival in CAN-2409 treated patients Biomarker data suggests association between immune cell activation and survival Topline

NEEDHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President

NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended

NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President